文献速递血管炎

年龄、抗凝药、高血压和心血管遗传特征可预测巨细胞动脉炎患者就诊时的颅部缺血并发症

Age, anticoagulants, hypertension and cardiovascular genetic traits predict cranial ischaemic complications in patients with giant cell arteritis.
PubMed 文献 · Ann Rheum Dis · 2025-01-02

在1946例巨细胞动脉炎(GCA)患者中,17%就诊时存在颅部缺血并发症。多变量分析显示抗凝治疗与并发症风险降低相关(校正OR=0.21),年龄≥80岁相比<60岁与风险升高相关(校正OR=1.60);剔除抗凝治疗后,高血压与并发症相关(校正OR=1.35)。作者认为年龄和高血压是危险因素,抗凝可能具有保护作用,但需进一步研究。

要点

  • 1946例GCA患者中17%就诊时有颅部缺血并发症。
  • 抗凝治疗与并发症风险降低独立相关(校正OR=0.21,95%CI 0.05–0.62)。
  • 年龄≥80岁相比<60岁与并发症风险升高相关(校正OR=1.60)。

核心结论

  • 年龄和高血压是GCA就诊时颅部缺血并发症的危险因素,但在本数据集中抗凝治疗似乎具有保护作用;定位基因作图提示免疫和凝血相关通路可能参与并发症的发病机制;在临床实践中应用前需进一步研究。

研究设计与样本

  • 纳入1946例具有就诊时临床人口学数据的GCA患者,检验既往心血管相关特征(包括心血管特征的多基因风险评分PRS)与颅部缺血并发症的关联,并使用弹性网络方法优化颅部缺血并发症模型,对相关PRS进行定位基因作图。

主要发现

  • 1946例GCA患者(中位年龄71岁,68.7%女性)中,17%就诊时有颅部缺血并发症。
  • 单变量分析中,10个变量与并发症相关(似然比检验p≤0.05)。
  • 多变量分析中,无论模型是否纳入PRS,效应最强的两个变量为抗凝治疗(校正OR=0.21,95%CI 0.05–0.62,p=4.95×10⁻³)和年龄(≥80岁相比<60岁,校正OR=1.60,95%CI 0.73–3.66,p=2.52×10⁻³)。
  • 在剔除抗凝治疗的敏感性分析中,年龄和高血压与就诊时颅部缺血并发症相关(高血压:校正OR=1.35,95%CI 1.03–1.75,p=0.03)。
  • 对一个相关的短暂性脑缺血发作PRS进行定位基因作图,识别出TEK、CD96和MROH9位点。

临床怎么用

  • 作者结论指出年龄和高血压是GCA就诊时颅部缺血并发症的危险因素,抗凝治疗在本数据集中似乎具有保护作用,但需进一步研究后方可应用于临床实践。

局限性

  • 原文结论指出需进一步研究后方可应用于临床实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This project aimed to determine whether cranial ischaemic complications at the presentation of giant cell arteritis (GCA) were associated with pre-existing cardiovascular (CV) risk factors, CV disease or genetic risk of CV-related traits. METHODS: 1946 GCA patients with clinicodemographic data at GCA presentation were included. Associations between pre-existing CV-related traits (including Polygenic Risk Scores (PRS) for CV traits) and cranial ischaemic complications were tested. A model for cranial ischaemic complications was optimised using an elastic net approach. Positional gene mapping of associated PRS was performed to improve biological understanding. RESULTS: In a sample of 1946 GCA patients (median age=71, 68.7% female), 17% had cranial ischaemic complications at presentation. In univariable analyses, 10 variables were associated with complications (likelihood-ratio test p≤0.05). In multivariable analysis, the two variables with the strongest effects, with or without PRS in the model, were anticoagulant therapy (adjusted OR (95% CI)=0.21 (0.05 to 0.62), p=4.95×10-3) and age (adjusted OR (95% CI)=1.60 (0.73 to 3.66), p=2.52×10-3, for ≥80 years versus <60 years). In sensitivity analyses omitting anticoagulant therapy from multivariable analysis, age and hypertension were associated with cranial ischaemic complications at presentation (hypertension: adjusted OR (95% CI)=1.35 (1.03 to 1.75), p=0.03). Positional gene mapping of an associated transient ischaemic attack PRS identified TEK, CD96 and MROH9 loci. CONCLUSION: Age and hypertension were risk factors for cranial ischaemic complications at GCA presentation, but in this dataset, anticoagulation appeared protective. Positional gene mapping suggested a role for immune and coagulation-related pathways in the pathogenesis of complications. Further studies are needed before implementation in clinical practice.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Chaddock NJM, Harden CJ, Sorensen L, et al. Age, anticoagulants, hypertension and cardiovascular genetic traits predict cranial ischaemic complications in patients with giant cell arteritis. Ann Rheum Dis. 2025. PMID: 39919905. doi:10.1136/ard-2024-225515

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。